

Name: Zonghai Li

Title: Professor

Institute: Shanghai Cancer Institute, Renji Hospital

Research Interests: Cancer biotherapy

Dr. Li is now a professor of State Key Lab of Oncogenes and Related Genes in Shanghai Cancer Institute. As a medical scientist, Dr. Li is dedicated himself to develop novel biological reagents for cancer treatments. He has identified novel isoform and variant of EGFR as well as a novel peptide ligand of EGFR. He developed novel monoclonal antibodies, bispecific antibodies as well as antibody-drug conjugates. Currently, his major interest is developing novel chimeric antigen receptor-engineered T cells (CAR-T). He has launched several CAR-T clinical trials for glioblastoma, hepatocellular carcinoma and other cancer types. He is now developing the next-generation of CAR-T cells to increase their safety and efficacy. He is also trying to understand the mechanism underlying the interaction of the microenvironment with the CAR-T cells.